At a glance
ClinicalIndex Comparison RecordPhase 2Active· 39 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Adrenocortical Carcinoma. Active but no longer recruiting, targeting 39 participants across 2 sites.
Detailed Summary
Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdrenocortical Carcinoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2Active
201620172018201920202021202220232024202520262027
Enrollment StartFeb 2016
First PostedFeb 2016
Primary CompletionJan 2019
TodayJul 2026
Study CompletionFeb 2027
First PostedFeb 3, 2016
Enrollment StartFeb 1, 2016
Primary CompletionJan 11, 2019
Study CompletionFeb 1, 2027
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.4 years ago
Interventions
Pembrolizumabdrug